TCGA-DK-A2I6-01A-12R-A18C-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 87.25361367
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.610
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.470
- MYC_TARGETS_V1+0.460
- OXIDATIVE_PHOSPHORYLATION+0.350
- MITOTIC_SPINDLE+0.310
- SPERMATOGENESIS+0.280
- MTORC1_SIGNALING+0.250
- TGF_BETA_SIGNALING+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.440
- INTERFERON_GAMMA_RESPONSE-0.390
- NOTCH_SIGNALING-0.230
- ALLOGRAFT_REJECTION-0.190
- PROTEIN_SECRETION-0.180
- IL2_STAT5_SIGNALING-0.160
- COMPLEMENT-0.150
- HEDGEHOG_SIGNALING-0.140
- P53_PATHWAY-0.130
- XENOBIOTIC_METABOLISM-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088878 | — | — | 0.856 |
| 2 | MDT-AP-0359 | Med | Medulloblastoma | 0.835 |
| 3 | MNG1082 | — | — | 0.813 |
| 4 | TCGA-OR-A5KY-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.812 |
| 5 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.807 |
| 6 | TCGA-77-8144-01A-11R-2247-07 | — | cohortSQ1 | 0.806 |
| 7 | TCGA-DQ-7588-01A-11R-2081-07 | — | — | 0.798 |
| 8 | AUR-AE6Y-TTM1-A-1-1-R-A742-41 | — | E | 0.794 |
| 9 | BS_8ZS9F31R | high-grade glioma | — | 0.791 |
| 10 | TCGA-18-5592-01A-01R-1635-07 | — | cohortSQ2 | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.610 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |